Indian pharmaceutical companies are entering global partnerships to produce a generic version of Gilead Sciences’ HIV prevention drug, with public health advocates urging that its launch be prioritized in India to improve patient access
Welcure Drugs & Pharmaceuticals stated on Monday that its board has analyzed and approved a proposal from Singapore's Telexcell Trade Pte to obtain as much as 25% of the company. The board noted that Telexcell will be considered solely as a...
Indian Immunologicals Limited (IIL) has introduced a gE-deleted DIVA marker vaccine for IBR (Infectious Bovine Rhinotracheitis), which is India's first indigenous option for this endemic disease in cattle. The IBR vaccine has been developed...
.jpeg "India, Russia Explore New Avenues in Pharma, Healthcare")
JP Nadda, Union Minister for Health & Family Welfare and Chemicals & Fertilizers, had a one-on-one discussion with H.E. Dmitry Nikolaevich Patrushev, Deputy Prime Minister of the Russian Federation, at Nirman Bhavan, New Delhi.
.jpeg "Fujifilm India Launches DR X-ray Facility to Boost Healthcare")
Fujifilm India has launched a digital radiology X-ray centre in the Community Health Centre (CHC) in Dholera, Gujarat
Wockhardt shares surged 7.45% to 1,435 following the publication of positive Phase 3 clinical trial results for its novel antibiotic Miqnaf (nafithromycin)
The results of a statewide review of 3.9 lakh lipid profile tests performed in the previous year have been made public by Metropolis Healthcare. According to the study, there has been a worrying change in the cardiovascular landscape of India
Global pharmaceutical giant Lupin Limited disclosed that its wholly owned subsidiary, Nanomi B.V., has executed a definitive agreement to acquire VISUfarma B.V., a specialty eye health company backed by GHO Capital Partners...
Syngene International has achieved a successful scale-up of the synthesis of a new active pharmaceutical ingredient for vascular calcification inhibition, progressing from lab-scale proof-of-concept to commercial-scale good manufacturing...
Moderna has conveyed that the primary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, the mRNA COVID-19 vaccine of their choice to the LP.8.1 variant of SARS-CoV-2, is in the positive range.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")